Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

The Food and Drug Administration has launched a safety review of two approved RSV drugs for infants, the latest immunizations ...

As an FDA official said that the agency has evidence that links COVID vaccines to the deaths of at least 10 children, the U.S ...

FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...

Sanofi (SNY) and AstraZeneca (AZN) stocks are in focus as FDA to review their infant RSV treatments following safety concerns ...

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for infants would face fresh safety scrutiny following ...

The preventive therapies would be the latest called into question under U.S. Health Secretary Robert F. Kennedy Jr., a long-time promoter of anti-vaccine views.

On the campaign trail last October, President Trump promised to let his health secretary, Robert F. Kennedy Jr., “go wild on ...

U.S. regulators are reexamining infant RSV antibody treatments as safety questions surface, prompting new FDA scrutiny of ...

Key Takeaways The U.S. Food and Drug Administration is reviewing two RSV drugs for infantsNo safety issues have been ...

FDA officials are newly scrutinizing several approved therapies to treat RSV in babies despite the fact that these shots were shown to be safe in clinical trials ...